Omnicell posts Q3 2026 profit above estimates but next-quarter guidance below forecasts
FROM THE WIRE · FINANCE.YAHOO.COM
OMCL Q3 deep dive: disciplined cost control offsets flat sales, software transition in early innings Healthcare tech company Omnicell (NASDAQ:OMCL) reported revenue ahead of Wall Street's expectations in Q3 2026, but sales were flat year on year at $307.9 million. On the other…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralMixed results: profit above consensus but revenue guidance below estimates may weigh on the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Third-quarter revenue was 307.9 million dollars, flat year on year.
- 02Non-GAAP earnings per share were 0.58 dollars versus 0.42 expected.
- 03Revenue guidance of 298 million is 4.3% below analyst estimates.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets